 Click here to access webcast replay Core 2022 development initiatives: Ongoing operation of Companys OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea CTD Initiation and completion in 2H 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure SBS-IF FDA conditional approval in December 2021 of CanaleviaTM-CA1 for treatment of chemotherapy-induced diarrhea CID in dogs Fourth quarter 2021 Mytesi net revenue was approximately 2.1 million versus approximately 0.6 million in the third quarter of 2021, an increase of 230 SAN FRANCISCO, CA ACCESSWIRE March 14, 2022 Jaguar Health, Inc. NASDAQ:JAGX today announced that the recording of the companys March 14, 2022, investor webcast regarding company updates and reported consolidated financial results for the year ended December 31, 2021 can be accessed by clicking here . About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, Napo Therapeutics Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. 